Biocompatible hydrogel treatments for retinal detachment
View Patent ↗Provided herein are in vivo gelling ophthalmic pre-formulations forming a biocompatible retinal patch comprising at least one nucleophilic compound or monomer unit, at least one electrophilic compound or monomer unit, and optionally a therapeutic agent and/or viscosity enhancer. In some embodiments, the retinal patch at least partially adheres to the site of a retinal tear. Also provided herein are methods of treating retinal detachment by delivering an in vivo gelling ophthalmic pre-formulation to the site of a retinal tear in human eye, wherein the in vivo gelling ophthalmic pre-formulation forms a retinal patch.
1. A method of delivering a therapeutic to an eye, the method comprising:
administering to the eye a therapeutic agent and a formulation comprising:
(a) multi-ARM nucleophilic polyol monomers having more than two nucleophilic arms, wherein each nucleophilic arm comprises a polyethyleneglycol chain and terminates in a nucleophilic amino group, wherein the nucleophilic arms of the multi-ARM nucleophilic polyol monomers are selected from
and wherein n is 1-200;
(b) multi-ARM electrophilic polyol monomers having more than two electrophilic arms, wherein each electrophilic arm comprises a polyethyleneglycol chain and terminates in an electrophilic succinimidyl group, wherein the electrophilic arms of the multi-ARM electrophilic polyol monomers are selected from
wherein m is 2 or 3 and wherein n is 1-200; and
(c) a viscosity enhancer selected from acacia, agar, bentonite, carbomers, carboxymethylcellulose calcium, ceratonia, cetostearyl alcohol, colloidal silicon dioxide, cyclomethicone, glyceryl behenate, guar gum, hectorite, hydrogenated vegetable oil type I, hydroxypropyl starch, hydroxypropylmethylcellulose, hydroxyethylcellulose, magnesium aluminum silicate, maltodextrin, polycarbophil, polydextrose, poly(methylvinyl ether/maleic anhydride), polyvinyl acetate phthalate, potassium chloride, propylene glycol alginate, saponite, sodium chloride, stearyl alcohol, sucrose, sulfobutylether β-cyclodextrin, tragacanth, and mixtures thereof.
2. The method of claim 1 , wherein the formulation polymerizes and/or gels at a target site of the eye.
3. The method of claim 1 , wherein the therapeutic agent is an immunosuppressive agent.
4. The method of claim 3 , wherein the immunosuppressive agent is a calcinuerin inhibitor, a mTor inhibitor, an anti-proliferative agent, a glucocorticosteroid, an antibody, or an agent acting on immunophilins.
5. The method of claim 3 , wherein the immunosuppressive agent is ciclosporin, tacrolimus, sirolimus, everolimus, azathioprine, mycophenolic acid, prednisolone, hydrocortisone, basiliximab, daclizumab; antithymocyte globulin (ATG), anti-lymphocyte globulin (ALG), rituximab, daclizumab, basiliximab, anakinra, rilonacept, ustekinumab, mepolizumab, tocilizumab, canakinumab, briakinumab, etanercept, infliximab, afelimomab, adalimumab, certolizumab pegol, golimumab, muromonab, mycophenolic acid, sirolimus, leflunomide, alefacept, everolimus, gusperimus, efalizumab, abetimus, natalizumab, abatacept, eculizumab, belimumab, fingolimod, belatacept, azathioprine, thalidomide, methotrexate, or lenalidomide.
6. The method of claim 1 , wherein the viscosity of the formulation is between about 5 cP and 4000 cP.
7. The method of claim 1 , wherein the multi-ARM nucleophilic polyol monomers are selected from
wherein R is hexaglycerol or tripentaerythritol; and
wherein n is 1-200.
8. The method of claim 1 , wherein the multi-ARM electrophilic polyol monomers are selected from
wherein R is hexaglycerol or tripentaerythritol; and
wherein n is 1-200.
9. The method of claim 2 , wherein the formulation is prepared from the following multi-ARM polyol monomers:
wherein R is hexaglycerol or tripentaerythritol; and
wherein n is such that the molecular weight of each of the polyol monomer is 20 kDa.
10. A pharmaceutical composition formulated for administration to an eye, the composition comprising a therapeutic and a formulation comprising:
(a) multi-ARM nucleophilic polyol monomers having more than two nucleophilic arms, wherein each nucleophilic arm comprises a polyethyleneglycol chain and terminates in a nucleophilic amino group, wherein the nucleophilic arms of the multi-ARM nucleophilic polyol monomers are selected from
and wherein n is 1-200;
(b) multi-ARM electrophilic polyol monomers having more than two electrophilic arms, wherein each electrophilic arm comprises a polyethyleneglycol chain and terminates in an electrophilic succinimidyl group, wherein the electrophilic arms of the multi-ARM electrophilic polyol monomers are selected from
wherein m is 2 or 3 and wherein n is 1-200; and
(c) a viscosity enhancer selected from acacia, agar, bentonite, carbomers, carboxymethylcellulose calcium, ceratonia, cetostearyl alcohol, colloidal silicon dioxide, cyclomethicone, glyceryl behenate, guar gum, hectorite, hydrogenated vegetable oil type I, hydroxypropyl starch, hydroxypropylmethylcellulose, hydroxyethylcellulose, magnesium aluminum silicate, maltodextrin, polycarbophil, polydextrose, poly(methylvinyl ether/maleic anhydride), polyvinyl acetate phthalate, potassium chloride, propylene glycol alginate, saponite, sodium chloride, stearyl alcohol, sucrose, sulfobutylether β-cyclodextrin, tragacanth, and mixtures thereof.
11. The composition of claim 10 , wherein the therapeutic agent is an immunosuppressive agent.
12. The composition of claim 11 , wherein the immunosuppressive agent is a calcinuerin inhibitor, a mTor inhibitor, an anti-proliferative agent, a glucocorticosteroid, an antibody, or an agent acting on immunophilins.
13. The composition of claim 11 , wherein the immunosuppressive agent is ciclosporin, tacrolimus, sirolimus, everolimus, azathioprine, mycophenolic acid, prednisolone, hydrocortisone, basiliximab, daclizumab, antithymocyte globulin (ATG), anti-lymphocyte globulin (ALG), rituximab, daclizumab, basiliximab, anakinra, rilonacept, ustekinumab, mepolizumab, tocilizumab, canakinumab, briakinumab, etanercept, infliximab, afelimomab, adalimumab, certolizumab pegol, golimumab, muromonab, mycophenolic acid, sirolimus, leflunomide, alefacept, everolimus, gusperimus, efalizumab, abetimus, natalizumab, abatacept, eculizumab, belimumab, fingolimod, belatacept, azathioprine, thalidomide, methotrexate, or lenalidomide.
14. The method of claim 1 , wherein the viscosity enhancer is hydroxypropylmethylcellulose or hydroxyethylcellulose.
15. The method of claim 1 , wherein the viscosity enhancer is hydroxypropylmethylcellulose.
16. The method of claim 5 , wherein the immunosuppressive agent is tacrolimus.
17. The composition of claim 10 , wherein the viscosity enhancer is hydroxypropylmethylcellulose or hydroxyethylcellulose.
18. The composition of claim 10 , wherein the viscosity enhancer is hydroxypropylmethylcellulose.
19. The composition of claim 10 , wherein the immunosuppressive agent is tacrolimus.
20. The method of claim 1 , wherein the formulation further comprises a buffer providing a pH range of about 6.0 to about 8.5.
21. The composition of claim 10 , wherein the formulation further comprises a buffer providing a pH range of about 6.0 to about 8.5.